Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58

Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer

Bayer (BAYRY) and Loxo Oncology (LOXO) announced updated clinical data for larotrectinib in adult and pediatric patients with TRK fusion cancer across 24 unique tumor types. The update included approximately one year of additional follow-up for a primary dataset of 55 patients as well as results from a supplementary dataset of 67 patients.1 The overall response rates in these groups were 80% and 81%, respectively, while the median duration of response had not yet been reached in either group. Complete responses in the primary dataset continued to mature, increasing to 18%, while the additional patients in the supplementary dataset experienced a CR rate of 17%. This is the only analysis to examine the efficacy and safety of a single-purpose drug for the treatment of TRK fusion cancer. The 122-patient integrated dataset included both adult and pediatric patients with TRK fusion cancer across 24 unique tumor types, ranging in age from approximately one month to 80 years. Tumor types included 10 distinct soft tissue sarcomas, salivary gland, infantile fibrosarcoma, thyroid, lung, melanoma, colon, gastrointestinal stromal tumor, breast, bone sarcoma, cholangiocarcinoma, carcinoma of unknown primary, congenital mesoblastic nephroma, appendiceal, and pancreas cancers. Safety results were generally consistent with previous presentations, with the majority of adverse events grade 1 or 2. No treatment-related grade 3 or 4 AEs occurred in more than 5 percent of patients. The U.S. Food and Drug Administration granted Priority Review for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase gene fusion. The FDA has set a target action date of November 26, 2018, under the Prescription Drug User Fee Act. Bayer has submitted a Marketing Authorization Application in the EU and additional filings in other markets are underway.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO Loxo Oncology
$160.01

-7.58 (-4.52%)

09/26/18
STFL
09/26/18
NO CHANGE
Target $217
STFL
Buy
Loxo data not 'transformational,' but keeps inspiring confidence, says Stifel
Stifel analyst Stephen Willey said the incremental follow-up data from Loxo Oncology's (LOXO) LIBRETTO-001 trial isn't "transformational," but it does confirm his confidence in the establishment of a high competitive hurdle for LOXO-292, which he sees being a "best-in-class" and first-to-market asset in a $1B+ market. He remains confident LOXO-292 is the superior asset, but acknowledges the anticipation of Blueprint Medicines' (BPMC) updated BLU-667 data at some point in late-FY18 to early-FY19 could serve as a bit of headwind on Loxo shares nearer to that data release. Willey keeps a Buy rating and $217 price target on Loxo shares.
10/07/18
PIPR
10/07/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo Oncology's 292 remains on top after RET data updates, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $200 price target for Loxo Oncology (LOXO) after the company provided an update of the thyroid patients in the Phase I/II study of LOXO-292. The analyst highlights that in the largest patient population the response rate increased from 45% to 59% with three additional patients responding between 9 and 12 months. Blueprint Medicines' (BPMC) competing BLU-667 reported a 49% ORR in a similar patient population and recall that adverse events of hypertension are still a concern, he notes. Van Buren believes that the 667's safety profile could continue to look worse as it continues to administer the drug to patients at higher doses and that treatment discontinuations could increase. Overall, the analyst believes Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety and could easily become a $1B+ drug.
10/08/18
IFSG
10/08/18
UPGRADE
IFSG
Outperform
Loxo Oncology upgraded to Outperform from Market Perform at IFS Securities
10/08/18
10/08/18
UPGRADE
Target $190

Outperform
Loxo Oncology upgraded to Outperform on LOXO-292 update at IFS Securities
As previously reported, IFS Securities analyst David Bouchey upgraded Loxo Oncology to Outperform from Market Perform, with $190 price target, after the company reported updated results from its Phase I/II trial for LOXO-292. The analyst believes the response rates for LOXO-292 continue to look "very strong," the safety data is "excellent" and early results show that these responses appear durable. So far, the drug has outperformed expectations, he adds.
BAYRY Bayer
$0.00

(0.00%)

08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.

TODAY'S FREE FLY STORIES

01:25
09/17/19
09/17
01:25
09/17/19
01:25
General news
FOMC outlook: »

FOMC outlook: the Fed…

01:25
09/17/19
09/17
01:25
09/17/19
01:25
General news
Asian Market Wrap: »

Asian Market Wrap:…

XLRN

Acceleron

$44.67

0.75 (1.71%)

22:05
09/16/19
09/16
22:05
09/16/19
22:05
Recommendations
Acceleron analyst commentary at Piper Jaffray »

Acceleron's ACE-083…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

PNRL

Paringa Resources

$2.28

-0.06 (-2.56%)

20:18
09/16/19
09/16
20:18
09/16/19
20:18
Hot Stocks
Paringa Resources names Jim Middleton as Executive Advisor »

Paringa Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBNC

Reliant Bancorp

$24.70

0.16 (0.65%)

20:17
09/16/19
09/16
20:17
09/16/19
20:17
Hot Stocks
Reliant Bancorp to buy Tennessee Community Bank Holdings for $37.2M »

Reliant Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

ORCL

Oracle

$53.12

-0.64 (-1.19%)

, INTC

Intel

$52.21

-0.32 (-0.61%)

19:12
09/16/19
09/16
19:12
09/16/19
19:12
Hot Stocks
Intel, Oracle collaborate on Optane DC Persistent Memory »

Intel (INTC) and Oracle…

ORCL

Oracle

$53.12

-0.64 (-1.19%)

INTC

Intel

$52.21

-0.32 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

ORCL

Oracle

$53.12

-0.64 (-1.19%)

, VMW

VMware

$155.87

4.81 (3.18%)

19:08
09/16/19
09/16
19:08
09/16/19
19:08
Hot Stocks
VMware, Oracle expand partnership on hybrid cloud »

Oracle (ORCL) and VMware…

ORCL

Oracle

$53.12

-0.64 (-1.19%)

VMW

VMware

$155.87

4.81 (3.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

ACRS

Aclaris Therapeutics

$1.09

0.06 (5.83%)

, BBCP

Concrete Pumping

$4.40

0.265 (6.41%)

19:05
09/16/19
09/16
19:05
09/16/19
19:05
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Aclaris…

ACRS

Aclaris Therapeutics

$1.09

0.06 (5.83%)

BBCP

Concrete Pumping

$4.40

0.265 (6.41%)

GLW

Corning

$30.04

-0.12 (-0.40%)

XLRN

Acceleron

$44.67

0.75 (1.71%)

SHOP

Shopify

$337.93

-0.77 (-0.23%)

KHC

Kraft Heinz

$29.62

0.37 (1.27%)

PSTV

Plus Therapeutics

$9.51

-0.05 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 18

    Sep

  • 01

    Oct

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

  • 17

    Sep

KHC

Kraft Heinz

$29.62

0.37 (1.27%)

19:03
09/16/19
09/16
19:03
09/16/19
19:03
Hot Stocks
3G Capital sells 25.1M shares of Kraft Heinz »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

KHC

Kraft Heinz

$29.62

0.37 (1.27%)

18:53
09/16/19
09/16
18:53
09/16/19
18:53
Hot Stocks
Kraft Heinz's Lemann acquires nearly 3.5M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

HMSY

HMS Holdings

$37.14

0.24 (0.65%)

18:43
09/16/19
09/16
18:43
09/16/19
18:43
Hot Stocks
HMS Holdings acquires VitreosHealth for approximately $36.5M »

HMS Holdings announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

18:25
09/16/19
09/16
18:25
09/16/19
18:25
General news
U.S. industrial production preview: »

U.S. industrial…

18:25
09/16/19
09/16
18:25
09/16/19
18:25
General news
Treasury Market Summary »

Treasury Market Summary:…

ICAD

iCAD

$6.89

-0.01 (-0.14%)

18:25
09/16/19
09/16
18:25
09/16/19
18:25
Conference/Events
iCAD to hold an investor reception »

Management hosts "An…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 12

    Nov

GLW

Corning

$30.04

-0.12 (-0.40%)

18:18
09/16/19
09/16
18:18
09/16/19
18:18
Hot Stocks
Corning down 5.5% or $1.64 at $28.40 per share after cutting volume outlook »

As part of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

18:17
09/16/19
09/16
18:17
09/16/19
18:17
Periodicals
We Company IPO delayed until October at earliest, WSJ reports »

The We Company's IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLW

Corning

$30.04

-0.12 (-0.40%)

18:16
09/16/19
09/16
18:16
09/16/19
18:16
Hot Stocks
Corning cuts Q3 volume guidance for Display and Optical Communications units »

Corning is providing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

18:05
09/16/19
09/16
18:05
09/16/19
18:05
Periodicals
Breaking Periodicals news story on We Company »

We Company IPO delayed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$37.21

-1.62 (-4.17%)

18:02
09/16/19
09/16
18:02
09/16/19
18:02
Periodicals
Auto workers strike could cost GM $100M daily, WSJ says »

General Motors could lose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLNE

Hamilton Lane

$59.95

-0.51 (-0.84%)

17:57
09/16/19
09/16
17:57
09/16/19
17:57
Hot Stocks
Hamilton Lane vice chairman sells 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

17:52
09/16/19
09/16
17:52
09/16/19
17:52
Conference/Events
SVB Leerink biotech analysts to hold analyst/industry conference call »

Biotech Analysts discuss…

HLNE

Hamilton Lane

$59.95

-0.51 (-0.84%)

17:52
09/16/19
09/16
17:52
09/16/19
17:52
Hot Stocks
Hamilton Lane chairman sells 78.5K shares of common »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GD

General Dynamics

$190.91

0.98 (0.52%)

, BAH

Booz Allen

$70.35

0.85 (1.22%)

17:44
09/16/19
09/16
17:44
09/16/19
17:44
Hot Stocks
General Dynamics, Booz Allen and Parsons awarded $427M max Air Force contract »

General Dynamics (GD),…

GD

General Dynamics

$190.91

0.98 (0.52%)

BAH

Booz Allen

$70.35

0.85 (1.22%)

PSN

Parsons

$37.25

0.35 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

T

AT&T

$37.32

-0.58 (-1.53%)

17:43
09/16/19
09/16
17:43
09/16/19
17:43
Periodicals
Suit claims AT&T told employees to make fake DirecTV accounts, Bloomberg says »

According to a lawsuit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

UBER

Uber

$34.42

1.18 (3.55%)

, LYFT

Lyft

$47.78

1.68 (3.64%)

17:39
09/16/19
09/16
17:39
09/16/19
17:39
Periodicals
Uber to limit drivers' app access in NYC to comply with rules, Reuters says »

Uber (UBER) on Tuesday…

UBER

Uber

$34.42

1.18 (3.55%)

LYFT

Lyft

$47.78

1.68 (3.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.